Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Q3 2026 Earnings Presentation
16 slides from Nova Eye Medical's earnings presentation, May 5, 2026
Slide 1: Nova Eye Medical Limited (ASX:EYE) Quarterly Report
Nova Eye Medical Limited (ASX:EYE) Investor Presentation Quarterly Report May 2026 nova-eye.com | 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Key Takeaways
Key Takeaways • Nova Eye's products address a genuine and growing clinical need. • Annual revenues of US$23 million - growing at 25%+ year on year - reflect real and sustained market demand. • This quarter showed that we can grow revenue while also improving profitability. • Just US$75,000 (1% of re
Slide 4: The Interventional Glaucoma Market Size & Our Position
The Interventional Glaucoma Market Size & Our Position Device market US$944M Pharma spend~ US$4.3B – 84M (2025) → US$1.6B (2030), People with declining 1) due to poor CAGR 10.6%(1) growing as a open - angle cases better alternative to pharma compliance low QOL Cataract link: Nova Eye stent free, tis
Slide 5: Competitive Position in the U.S.
Competitive Position in the U.S. iTrack Advance: FDA-cleared 2023; Why Do Surgeons Choose iTrack Advance? no implant, no foreign material • Procedure: Canaloplasty – restores natural drainage • Complements cataract surgery; (“angioplasty of the eye”). preserves tissue • FDA approved to treat glaucom
Slide 6: Regional Sales for Quarter (US$’000s)
Regional Sales for Quarter (US$’000s) Q3FY25 Q3FY26 Q3FY26 Growth on Q3FY26 (US$’000’s) (US$’000’s) PCP (A$’000’s)(1) USA 3,529 4,503 28% 6,400 Germany 596 533 -10% 759 Direct 4,125 5,037 22% 7,159 ROW 551 594 8% 842 Sales (excl China) 4,676 5,630 21% 8,001 China - 130 184 Total 4,676 5,760 23% 8,18
Slide 7: Last 12 Months (LTM) Revenue US$’000s
Last 12 Months (LTM) Revenue US$’000’s LTM April 2025 LTM April 2026 Growth LTM (US$’000’s) (US$’000’s) YoY USA 13,820 17,758 28% Trailing twelve- month revenues Germany 1,782 1,851 4% continue to grow Direct 15,602 19,608 26% and following ROW 1,464 2,038 39% record sales in April 2026 Sales (excl
Slide 8: Drivers of recent sales growth
Drivers of recent sales growth • Marketing driving brand and product awareness (ASCRS). • Sales team productivity. • Release of illuminated catheter with proprietary (patent pending) Green Light to provide clearer view for better navigation of the catheter through the canal of Schlemm. • Release of
Slide 9: China: iTrack Advance Approved. Significant opportunity ahead.
China: iTrack Advance Approved. Significant opportunity ahead. • iTrack Advance received China NMPA approval September 2025; first sales made February 2026. • China performs 3.6 million cataract surgeries annually(1) - in a population of 1.4 billion people. • The USA performs 4.9 million surgeries(1
Slide 10: USA Sales Growth Summary US$
USA Sales Growth Summary US$ Sales by Quarter in USA and revenue per sales representative (RPR)) $5,000,000 $4,500,000 $4,000,000 $3,500,000 Compound $3,000,000 quarterly $2,500,000 revenue $2,000,000 growth rate in $1,500,000 USA of ~6% $1,000,000 $500,000 $- Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY
Slide 11: Operating Result
Operating Result Delivering sales growth and improved operating results (1) FX AUD to USD of 0.65 • Operating leverage is working: the ratio of operating expenditure to sales continues to improve as revenue scales and cost discipline holds. (2) FX AUD to USD of 0.70 • US$96,000 positive EBITDA recor
Slide 12: Revenue and EBITDA history by quarter US$
Revenue and EBITDA history by quarter US$ 6,000,000 5,000,000 Revenue quarterly 4,000,000 growth rate across 7 quarters of 4.5%, 3,000,000 historically strong 2,000,000 sales in Q4, support the achievability of 1,000,000 revenue and EBITDA guidance - Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26
Slide 13: Cash outflow from operations A$’000’s
Cash outflow from operations A$’000’s Q3 FY26 Q3FY26 adjusted Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1FY26 Q2FY26 reported for WC - -500 Cash Outflow in A$000s per qtr -1,000 -1,500 -2,000 -2,500 -3,000 • A$0.6 million of the outflow represents advance payments for 2026 marketi
Slide 14: Recap and sales guidance
Recap and sales guidance Previous Guidance (March 2026) Sales Guidance updated 5 May 2026 • FY26 sales revenue (excl. China) of between • Achieved record sales in April 2026 US$21 million and US$22 million • LTM sales revenue (excl. China) for the • A$30.9 million to A$32.4 million twelve (12) month
Slide 15: Recap and guidance operating results
Recap and guidance operating results Most Recent Guidance Guidance 5 May 2026 Targeting breakeven EBITDA in H2FY26 • Continued improvement in operating result through Q3FY26, including positive EBITDA for the four (4) months to 31 March 2026. • Breakeven to small positive EBITDA in H2FY26 and positi
Slide 16: Tom Spurling, Mark Flynn
Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8836 0193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com nova-eye.com | 16